Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wav
Clinical Trial Grant
Administered By
Pediatrics, Neurology
Awarded By
Neurocrine Biosciences, Inc.
Start Date
November 19, 2021
End Date
October 31, 2023
Administered By
Pediatrics, Neurology
Awarded By
Neurocrine Biosciences, Inc.
Start Date
November 19, 2021
End Date
October 31, 2023